Harmony Biosciences Holdings, Inc. (HRMY) key performance indicators and operating metrics (6 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Average Number of Patients | 8.5K | FY2026-Q1 |
| Adjusted Diluted Earnings per Share (Non-GAAP) | 1.08 USD_per_share | FY2025-Q3 |
| Adjusted Net Income (Non-GAAP) | 63.5M | FY2025-Q3 |
| Wakix Net Revenue Guidance (2025) | 239M | FY2025-Q3 |
| Year-over-Year Net Product Revenue Growth | 29.00 percent | FY2025-Q3 |
| Average Patients on Wakix | 7.2K | FY2025-Q1 |
Back to HRMY overview · HRMY earnings · HRMY holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.